NASDAQ:AGEN
Agenus Inc. Stock News
$10.86
+0.360 (+3.43%)
At Close: May 17, 2024
Agenus to Participate in B. Riley Securities' Oncology Investor Conference
12:09pm, Tuesday, 19'th Jan 2021
LEXINGTON, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
XOMA: A Royalty Aggregator To Watch
04:43pm, Monday, 04'th Jan 2021
XOMA: A Royalty Aggregator To Watch
Completion of Balstilimab BLA Filing Extended To 1H2021
07:45am, Thursday, 03'rd Dec 2020
Agenus to fulfill FDA feedback for six-month follow-up on late responders Agenus to fulfill FDA feedback for six-month follow-up on late responders
Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference
01:28pm, Wednesday, 25'th Nov 2020
LEXINGTON, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
Agenus to Participate in Fireside Chat at the Jefferies 2020 Virtual London Healthcare Conference
07:04pm, Monday, 16'th Nov 2020
LEXINGTON, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
Agenus: A Buy With iNKT Therapy, MK-4830 Milestone
11:09pm, Friday, 13'th Nov 2020
Agenus is nearing multiple upward inflection points. iNKT therapy trial started, showing immunotherapy leadership.
Agenus and Dr. Steven O'Day to Participate in Webcast Hosted by William Blair on AGEN1181 and SITC Data
02:43pm, Friday, 13'th Nov 2020
LEXINGTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccine
An Agenus-discovered first-in-class ILT4 antibody, MK-4830, enters Phase 2
08:45am, Tuesday, 10'th Nov 2020
LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
Agenus Presents Additional Clinical Responses and Novel Biomarker Data at SITC2020
08:15am, Monday, 09'th Nov 2020
LEXINGTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccine
Why Agenus Stock Is Popping Today
02:39pm, Monday, 02'nd Nov 2020
An off-the-shelf cell therapy for COVID-19 is sending the biotech's shares higher today.
Agenus Doses First COVID-19 Patient with iNKT Cell Therapy
08:45am, Monday, 02'nd Nov 2020
LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers and infe
Agenus Inc. (AGEN) CEO Garo Armen on Q3 2020 Results - Earnings Call Transcript
04:02pm, Thursday, 29'th Oct 2020
Agenus Inc. (AGEN) CEO Garo Armen on Q3 2020 Results - Earnings Call Transcript
Agenus R&D Update & Third Quarter Financial Report
07:45am, Thursday, 29'th Oct 2020
LEXINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines
Exclusive: U.S. trial of AstraZeneca COVID-19 vaccine may resume this week - sources
12:00am, Tuesday, 20'th Oct 2020
Exclusive: U.S. trial of AstraZeneca COVID-19 vaccine may resume this week - sources
Remdesivir has ‘little or no effect’ in reducing coronavirus deaths, WHO says
12:48pm, Friday, 16'th Oct 2020
A study coordinated by the World Health Organization has indicated that remdesivir, along with three other potential drug treatments for the coronavirus, has "little or no effect" on death rates among
